Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Hu14.18K322A |
| Synonyms | |
| Therapy Description |
Hu14.18K322A is a monoclonal antibody that binds GD2 and activates immune response to tumor cells expressing GD2, potentially resulting in increased tumor cell death (PMID: 32169872, PMID: 31601569). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Hu14.18K322A | GD2 Antibody 6 | Hu14.18K322A is a monoclonal antibody that binds GD2 and activates immune response to tumor cells expressing GD2, potentially resulting in increased tumor cell death (PMID: 32169872, PMID: 31601569). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT01857934 | Phase II | Doxorubicin Sargramostim Aldesleukin Vincristine Sulfate Filgrastim Tretinoin Levetiracetam Cisplatin + Etoposide Hu14.18K322A Busulfan + Melphalan Cyclophosphamide + Topotecan | Therapy for Children With Advanced Stage Neuroblastoma | Active, not recruiting | USA | 0 |